Gene
AR
AR is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (100), Actionable biomarkers (12), Trial mentions (527), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention AR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with a planned future start and 3 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 dated before 1990 and 89 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 68 of 8,738 | 0.78% | not measured | |
| 2025 | 53 of 8,875 | 0.60% | not measured | |
| 2024 | 46 of 8,597 | 0.54% | not measured | |
| 2023 | 40 of 8,275 | 0.48% | 86 of 11,460 | 0.75% |
| 2022 | 29 of 8,285 | 0.35% | 97 of 13,598 | 0.71% |
| 2021 | 41 of 8,692 | 0.47% | 125 of 15,045 | 0.83% |
| 2020 | 27 of 7,640 | 0.35% | 101 of 14,459 | 0.70% |
| 2019 | 38 of 7,300 | 0.52% | 87 of 12,159 | 0.72% |
| 2018 | 22 of 6,927 | 0.32% | 75 of 11,854 | 0.63% |
| 2017 | 26 of 6,558 | 0.40% | 85 of 11,595 | 0.73% |
Showing 10 of 37 years.
Assay-provider ledger (100)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
| OmixScience Co., Ltd | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 06, 2026 |
| OmixScience Research Institute | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 06, 2026 |
| AmoyDx | Diagnostic provider | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| Horizon | Reagent supplier | Clinical validationAnalytical validation | 1 | December 08, 2025 |
Showing 5 of 100 assay-provider companies.
Actionable biomarkers (12)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| AR overexpression | 4ohtestosterone | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| AR overexpression | Bicalutamide | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| AR overexpression | Enzalutamide | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| AR overexpression | Orterone | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| AR (F877L) + AR (T878A) | Enzalutamide | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Showing 5 of 12 actionable-biomarker assertions.
Trial mentions (527)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01852786 | Trial biospecimen (AACT) |
| NCT04769817 | Trial biospecimen (AACT) |
| NCT05032040 | Trial eligibility (AACT) |
| NCT05647564 | Trial eligibility (AACT) |
| NCT06764485 | Trial eligibility (AACT) |
Showing 5 of 527 trial mentions.
Target-disease associations (1,129)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-methylglutaconic aciduria type 4 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 45,X/46,XY mixed gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX disorder of sex development - anorectal anomalies | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 1,129 associations.
Vendor sourcing (1,804)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.0.0 dataset. In silico tool predictions suggest damaging effect of the variant on gene or gene product [REVEL: 0... | View ClinVar record SCV002058324.2 |
| A2A (Italy) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Adults ≥ 18 years of age. 2. Patient has histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors with TP53 m... | View trial NCT06136884 |
| A2A (Italy) | Trial sponsor | Mentioned in trial textTrial free-text mention | Androgen receptor | View trial NCT06136884 |
| AOBiome Therapeutics, Inc. (United States) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Female subjects who are pregnant or lactating or who are trying to conceive 2. Female subjects with a positive urine β-human chorionic gonadotropin (β-... | View trial NCT02656485 |
| AOBiome Therapeutics, Inc. (United States) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Use of topical acne treatments, including benzoyl peroxide within 2 weeks prior to randomization to end of follow-up, retinoids (e.g., tretinoin, tazar... | View trial NCT07866105 |
Showing 5 of 1,804 sourcing records.
Trial-cited literature (1,372)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. | Annals of oncology : official journal of the European Society for Medical Oncology | 2026 | 29 |
| PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy. | The Prostate | 2026 | 2 |
| Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. | The Lancet. Oncology | 2026 | 1 |
| Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809). | The Prostate | 2026 | 0 |
| Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins. | Prostate cancer | 2026 | 0 |
Showing 5 of 1,372 papers.
Protein variant mentions (112)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A141T | 1 | 2015 | PMID 25741868 |
| p.A20N | 1 | 2008 | PMID 18471323 |
| p.A211T | 1 | 2015 | PMID 25741868 |
| p.A385S | 1 | 2015 | PMID 25741868 |
| p.A475V | 1 | 2015 | PMID 25741868 |
Showing 5 of 112 variants.
Literature-extracted relations (573)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Abiraterone | Chemical | negative_correlate |
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. | 2025 |
| PREDNISOLONE | Chemical | negative_correlate |
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. | 2025 |
| Prednisone | Chemical | negative_correlate |
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. | 2025 |
| Dutasteride | Chemical | negative_correlate |
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. | 2024 |
| Testosterone | Chemical | interact |
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. | 2024 |
Showing 5 of 573 relation assertions.
Organizations publishing (836)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 86 | 2004 to 2025 |
| Dana-Farber Cancer Institute | Other | 50 | 2014 to 2025 |
| Government of the United States of America | Government | 48 | 2009 to 2025 |
| University of Washington | Academic | 41 | 2008 to 2025 |
| Institut Gustave Roussy | Other | 39 | 2014 to 2026 |
Showing 5 of 836 organizations.
Where AR appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
962 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.